Hympavzi
Payments companies reported to CMS as associated with Hympavzi. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Hympavzi, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Hympavzi
These are the largest totals companies reported as associated with Hympavzi. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Akshat Jain | Redlands, CA | Pediatric Hematology-Oncology | $72,375.43 |
| Maissaa Janbain | New Orleans, LA | Hematology & Oncology | $36,251.86 |
| Vivek Sharma | Louisville, KY | Hematology & Oncology | $27,350.97 |
| Ashok Raj | Louisville, KY | Pediatric Hematology-Oncology | $25,503.93 |
| Steven Pipe | Ann Arbor, MI | Pediatric Hematology-Oncology | $17,750.00 |
| Guy Young | Bozeman, MT | Pediatric Hematology-Oncology | $16,821.71 |
| Kim Schafer | Sacramento, CA | Family | $14,874.32 |
| Tammuella Chrisentery-Singleton | New Orleans, LA | Pediatric Hematology-Oncology | $13,517.30 |
| Robert Sidonio | Atlanta, GA | Pediatric Hematology-Oncology | $13,508.35 |
| Christopher Walsh | New York, NY | Hematology & Oncology | $13,500.00 |
Prescribed Hympavzi?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.